Overview

Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing Cholangitis

Status:
Completed

Trial end date:
2015-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this research study is to determine whether the combination of UDCA and ATRA taken for 3 months will improve laboratory tests of liver and bile duct inflammation in patients with Primary Sclerosing Cholangitis (PSC). Our hypothesis is that a combination of these medications will improve the liver inflammatory tests in these patients, specifically a reduction in alkaline phosphatase (AP) by at least 30%.

Phase:

Phase 1

Details

Lead Sponsor:

Yale University

Collaborator:

Mayo Clinic

Treatments:

Tretinoin
Ursodeoxycholic Acid